Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3721185rdf:typepubmed:Citationlld:pubmed
pubmed-article:3721185lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C0014710lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C1709100lld:lifeskim
pubmed-article:3721185lifeskim:mentionsumls-concept:C0112370lld:lifeskim
pubmed-article:3721185pubmed:issue3lld:pubmed
pubmed-article:3721185pubmed:dateCreated1986-7-25lld:pubmed
pubmed-article:3721185pubmed:abstractTextThe interaction between ergotamine 3 and 30 micrograms/kg i.v. and darodipine (PY108-068) 30 micrograms/kg i.v. was studied in anaesthetized cats. Ergotamine decreased heart rate, cardiac output and total peripheral conductance dose-dependently. Ergotamine caused regional vasoconstriction (measured with tracer microspheres) in the heart, kidneys, adrenals, liver, spleen, skin and arterio-venous shunts but dilatation in the pancreas and skeletal muscle, possibly attributable to serotoninergic stimulation. Darodipine reversed most ergotamine effects except those on the spleen, skin and arterio-venous shunts. Since constriction of arterio-venous shunts was not inhibited, ergotamine is unlikely to lose its effectiveness in migraine patients under concomitant dihydropyridine treatment, while unwanted vasoconstrictor effects are likely to be diminished.lld:pubmed
pubmed-article:3721185pubmed:languageenglld:pubmed
pubmed-article:3721185pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3721185pubmed:citationSubsetIMlld:pubmed
pubmed-article:3721185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3721185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3721185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3721185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3721185pubmed:statusMEDLINElld:pubmed
pubmed-article:3721185pubmed:issn0306-3623lld:pubmed
pubmed-article:3721185pubmed:authorpubmed-author:KouD HDHlld:pubmed
pubmed-article:3721185pubmed:authorpubmed-author:HodCClld:pubmed
pubmed-article:3721185pubmed:issnTypePrintlld:pubmed
pubmed-article:3721185pubmed:volume17lld:pubmed
pubmed-article:3721185pubmed:ownerNLMlld:pubmed
pubmed-article:3721185pubmed:authorsCompleteYlld:pubmed
pubmed-article:3721185pubmed:pagination309-14lld:pubmed
pubmed-article:3721185pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:meshHeadingpubmed-meshheading:3721185-...lld:pubmed
pubmed-article:3721185pubmed:year1986lld:pubmed
pubmed-article:3721185pubmed:articleTitleMutual inhibition and synergistic effects of ergotamine and the calcium antagonist darodipine.lld:pubmed
pubmed-article:3721185pubmed:publicationTypeJournal Articlelld:pubmed